OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’-Reference-Cited by-同舟云学术

OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’

Published:2015-06-18 Issue:10 Volume:70 Page:2779-2786
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:J. Antimicrob. Chemother.

Author:

Morinaka Akihiro,Tsutsumi Yuko,Yamada Mototsugu,Suzuki Kenji,Watanabe Takashi,Abe Takao,Furuuchi Takeshi,Inamura Seiichi,Sakamaki Yoshiaki,Mitsuhashi Nakako,Ida Takashi,Livermore David M.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Reference33 articles.

1. Proliferation and significance of clinically relevant β-lactamases

2. Updated Functional Classification of β-Lactamases

3. Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention

4. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

5. Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New antibiotics in clinical pipeline for treating infections caused by metallo-β-lactamases producing Gram-negative bacteria;Current Opinion in Infectious Diseases;2024-08-01

2. Impact of chromosomally encoded resistance mechanisms and transferable β-lactamases on the activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa;Journal of Antimicrobial Chemotherapy;2024-07-29

3. Evolving resistance landscape in gram‐negative pathogens: An update on β‐lactam and β‐lactam‐inhibitor treatment combinations for carbapenem‐resistant organisms;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

4. Therapies in preclinical and in early clinical development for the treatment of urinary tract infections: from pathogens to therapies;Expert Opinion on Investigational Drugs;2024-05-09

5. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions;International Journal of Antimicrobial Agents;2024-05